Trial Profile
A Randomized Phase 2/3 Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemotherapy Versus Chemotherapy Alone for the Treatment of Patients With Metastatic or Locally Recurrent Triple-Negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; ERY-ASP (Primary) ; Gemcitabine (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms TRYbeCA-2
- Sponsors ERYtech Pharma
- 04 Oct 2023 This trial has been completed in Spain.
- 12 Sep 2022 According to an ERYtech Pharma media release, The trial's Steering Committee met to review the results of the 25 evaluable patients.
- 25 May 2022 This trial has been completed in Hungary, according to European Clinical Trials Database record.